PMID- 18777490
OWN - NLM
STAT- MEDLINE
DCOM- 20081003
LR  - 20220330
IS  - 1479-1641 (Print)
IS  - 1479-1641 (Linking)
VI  - 5
IP  - 3
DP  - 2008 Sep
TI  - The safety and tolerability of atorvastatin 10 mg in the Collaborative 
      Atorvastatin Diabetes Study (CARDS).
PG  - 177-83
LID - 10.3132/dvdr.2008.029 [doi]
AB  - The objective of this study was to evaluate the safety and tolerability of 
      atorvastatin 10 mg compared with placebo in 2,838 patients with type 2 diabetes 
      and no history of coronary heart disease who were enrolled in the Collaborative 
      Atorvastatin Diabetes Study (CARDS) and followed for 3.9 years. The percentages 
      of patients experiencing treatment-associated adverse events (AEs), serious AEs 
      and discontinuations due to AEs in the atorvastatin (n=1,428) and placebo 
      (n=1,410) groups were 23.0% vs. 25.4%, 1.1% vs. 1.1% and 2.9% vs. 3.4%, 
      respectively. The most common treatment-associated AEs in the atorvastatin and 
      placebo groups were digestive system-related (8.9% vs. 10.0%). All-cause and 
      treatment-associated myalgia were reported in 4.0% and 1.0% of 
      atorvastatin-treated patients, and 4.8% and 1.2% of placebo-treated patients. An 
      analysis of selected AEs by tertiles of baseline low-density lipoprotein (LDL) 
      cholesterol showed no relationship between LDL cholesterol levels and the 
      incidence of myalgia, cancer or nervous system AEs in either treatment group. 
      Overall, these data demonstrate that atorvastatin 10 mg was well tolerated in 
      patients with type 2 diabetes during long-term treatment.
FAU - Newman, Connie B
AU  - Newman CB
AD  - Department of Medicine, New York University School of Medicine, VA Hospital, 423 
      East 23rd Street, Dept of Medicine -11093 South, New York, NY 10010, USA.
FAU - Szarek, Michael
AU  - Szarek M
FAU - Colhoun, Helen M
AU  - Colhoun HM
FAU - Betteridge, D John
AU  - Betteridge DJ
FAU - Durrington, Paul N
AU  - Durrington PN
FAU - Hitman, Graham A
AU  - Hitman GA
FAU - Neil, H Andrew W
AU  - Neil HA
FAU - Demicco, David A
AU  - Demicco DA
FAU - Auster, Sheila
AU  - Auster S
FAU - Fuller, John H
AU  - Fuller JH
CN  - Cards Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00327418
GR  - Department of Health/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research
JID - 101234011
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pyrroles)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Atorvastatin
MH  - Cholesterol, LDL/blood
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Double-Blind Method
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - Heptanoic Acids/administration & dosage/*adverse effects
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*adverse 
      effects
MH  - Ireland
MH  - Male
MH  - Middle Aged
MH  - Muscular Diseases/chemically induced
MH  - Practice Guidelines as Topic
MH  - Pyrroles/administration & dosage/*adverse effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - United Kingdom
EDAT- 2008/09/09 09:00
MHDA- 2008/10/04 09:00
CRDT- 2008/09/09 09:00
PHST- 2008/09/09 09:00 [pubmed]
PHST- 2008/10/04 09:00 [medline]
PHST- 2008/09/09 09:00 [entrez]
AID - 3115 [pii]
AID - 10.3132/dvdr.2008.029 [doi]
PST - ppublish
SO  - Diab Vasc Dis Res. 2008 Sep;5(3):177-83. doi: 10.3132/dvdr.2008.029.